Literature DB >> 10534604

Hyposecretion of adrenal androgens and the relation of serum adrenal steroids, serotonin and insulin-like growth factor-1 to clinical features in women with fibromyalgia.

P H Dessein1, E A Shipton, B I Joffe, D P Hadebe, A E Stanwix, B A Van der Merwe.   

Abstract

Neuroendocrine deficiencies have been implicated in fibromyalgia (FM). In the present study, adrenal androgen metabolites and their relationship with health status in FM were investigated. For comparison, serum levels of other implicated neuroendocrine mediators were correlated with health status. Fifty-seven consecutive women with FM completed the Fibromyalgia Impact Questionnaire (FIQ). Fasting blood samples were taken for measurement of dehydroepiandrosterone sulphate (DHEAS), free testosterone (T), cortisol, serotonin and insulin-like growth factor-1. Normal value for DHEAS and T were obtained from 114 controls. DHEAS levels were decreased significantly in pre- and postmenopausal patients (P<0.0001 and P<0.0005, respectively). T levels were decreased significantly in premenopausal and insignificantly in postmenopausal patients (P<0.0001 and P=0.06, respectively). The following correlations between neurohormonal levels and FIQ scores were found: DHEAS (after adjustment for age) vs. pain (P<0.001) and T (after adjustment for age) versus physical functioning (P=0.002). None of the other neurohormonal levels correlated significantly with any of the FIQ scores. IGF-1 levels were lower in the obese patients as compared to those who were non-obese (P=0.03). The BMI correlated positively with pain (P<0. 001) and inversely with DHEAS levels (P=0.006). After further adjustment for BMI, the correlation between age adjusted DHEAS and pain was no longer significant. Hyposecretion of adrenal androgens was documented in FM. This was more pronounced in obese patients. Low serum androgen levels correlated with poor health status in FM. Longitudinal studies are needed to elucidate whether these are cause and/or effect relationships.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10534604     DOI: 10.1016/s0304-3959(99)00113-x

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  15 in total

1.  Nociceptive aspects of fibromyalgia.

Authors:  A A Larson; K J Kovács
Journal:  Curr Pain Headache Rep       Date:  2001-08

2.  Delineating psychological and biomedical profiles in a heterogeneous fibromyalgia population using cluster analysis.

Authors:  Barbara L Loevinger; Elizabeth A Shirtcliff; Daniel Muller; Carmen Alonso; Christopher L Coe
Journal:  Clin Rheumatol       Date:  2011-12-27       Impact factor: 2.980

Review 3.  The role of gender in fibromyalgia syndrome.

Authors:  M B Yunus
Journal:  Curr Rheumatol Rep       Date:  2001-04       Impact factor: 4.592

Review 4.  Complementary and alternative therapies for fibromyalgia.

Authors:  L J Crofford; B E Appleton
Journal:  Curr Rheumatol Rep       Date:  2001-04       Impact factor: 4.592

Review 5.  Growth hormone in musculoskeletal pain states.

Authors:  Robert Bennett
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

Review 6.  Fibromyalgia: A Critical and Comprehensive Review.

Authors:  Andrea T Borchers; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

Review 7.  Growth hormone in musculoskeletal pain states.

Authors:  Robert Bennett
Journal:  Curr Pain Headache Rep       Date:  2005-10

8.  Elevated levels of gonadotrophins but not sex steroids are associated with musculoskeletal pain in middle-aged and older European men.

Authors:  Abdelouahid Tajar; John McBeth; David M Lee; Gary J Macfarlane; Ilpo T Huhtaniemi; Joseph D Finn; Gyorgy Bartfai; Steven Boonen; Felipe F Casanueva; Gianni Forti; Aleksander Giwercman; Thang S Han; Krzysztof Kula; Fernand Labrie; Michael E J Lean; Neil Pendleton; Margus Punab; Alan J Silman; Dirk Vanderschueren; Terence W O'Neill; Frederick C W Wu
Journal:  Pain       Date:  2011-03-21       Impact factor: 6.961

Review 9.  Fibromyalgia: symptom constellation and potential therapeutic options.

Authors:  Marjorie L Shuer
Journal:  Endocrine       Date:  2003-10       Impact factor: 3.925

10.  Decrease of Serum IGF-1 Level is Not Associated With Obstructive Sleep Apnea in Fibromyalgia Patients.

Authors:  Emrullah Hayta; Ayşe Altun Okşaşoğlu
Journal:  Arch Rheumatol       Date:  2016-10-19       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.